Enhancing Attention and Wellbeing Using Digital Therapeutics

a study on Mild Cognitive Impairment Cognitive Decline Meditation

Summary

Eligibility
for people ages 60-99 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at San Francisco, California
Dates
study started
study ends around
Principal Investigator
by Adam Gazzaley, MD/PhDDavid Ziegler, PhD
Headshot of Adam Gazzaley
Adam Gazzaley

Description

Summary

The goals of the proposed research are to first determine the minimal and/or optimal dose of a digital intervention required for cognitive enhancement, and then to examine the impact of several potential moderators of treatment effects (i.e., cognitive decline, AD polygenic hazard score, cardiovascular risk, and race/ethnicity). This knowledge gained from his high-impact study with transform the field of cognitive interventions, paving the way for a precision medicine model for cognitive enhancing interventions that improve quality of life for older adults and individuals with cognitive deficits at risk of developing dementia.

Official Title

Optimizing a Closed-loop Digital Meditation Intervention for Remediating Cognitive Decline and Reducing Stress in Older Adults

Keywords

Aging, MCI, Cognitive Decline, healthy aging, attention, cognition, dementia, intervention, digital, behavioral, prevention, decline, stress reduction, Quality of life, Cognitive Dysfunction, MediTrain, Worder, MediTrain 30m/day for 6wks, MediTrain 15m/day for 6wks, MediTrain 30m/day for 3wks, MediTrain 15m/day for 3wks

Eligibility

You can join if…

Open to people ages 60-99

  • 60+ years old (adult)
  • English language fluency
  • owning a smartphone or tablet

You CAN'T join if...

  • Under 60 years old (minor)

Location

  • UCSF accepting new patients
    San Francisco California 94158 United States

Lead Scientists at UCSF

  • Adam Gazzaley, MD/PhD
    Dr. Adam Gazzaley obtained an M.D. and Ph.D. in Neuroscience at the Mount Sinai School of Medicine in New York, completed Neurology residency at the University of Pennsylvania, and postdoctoral training in cognitive neuroscience at University of California, Berkeley.
  • David Ziegler, PhD

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT06397469
Study Type
Interventional
Participants
Expecting 4000 study participants
Last Updated
Contact us about this trial